Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm
21. November 2024 13:34 ET
|
KUEHN LAW, PLLC
NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Relmada Therapeutics, Inc. (NASDAQ: RLMD)...
Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm
05. September 2024 09:29 ET
|
KUEHN LAW, PLLC
NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Relmada Therapeutics, Inc. (NASDAQ: RLMD)...
RLMD INVESTOR NEWS: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Relmada Therapeutics, Inc. Investors With Losses to Inquire About Securities Class Action Investigation – RLMD
10. Juni 2023 16:59 ET
|
The Rosen Law Firm PA
NEW YORK, June 10, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Relmada...
Bragar Eagel & Squire, P.C. Is Investigating Relmada, Bowlero, and Integra and Encourages Investors to Contact the Firm
04. Juni 2023 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, June 04, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Relmada Therapeutics, Inc....
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Relmada Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – RLMD
03. Juni 2023 12:12 ET
|
The Rosen Law Firm PA
NEW YORK, June 03, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Relmada...
Bragar Eagel & Squire, P.C. Is Investigating Relmada, and Sanmina and Encourages Investors to Contact the Firm
19. Mai 2023 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, May 19, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Relmada Therapeutics, Inc....
Bragar Eagel & Squire, P.C. Is Investigating Fox, Cutera, and Relmada and Encourages Investors to Contact the Firm
14. Mai 2023 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, May 14, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fox Corporation (NASDAQ:...
Relmada Therapeutics Set for Busy 2015 in Clinical Trials Developing Drugs for the Lucrative Pain Market
02. April 2015 08:30 ET
|
Relmada Therapeutics, Inc.
NEW YORK, NY--(Marketwired - April 02, 2015) - Relmada Therapeutics, Inc. (OTCQB: RLMD) has quite a busy 2015 ahead of it in the clinic. The pharmaceutical company has stepped up its work in a big...
Relmada Therapeutics Adds $15 Million in Capital to Expedite Development of Pain Treatment Drugs
29. Oktober 2014 09:00 ET
|
Relmada Therapeutics, Inc.
NEW YORK, NY--(Marketwired - October 29, 2014) - Relmada Therapeutics, Inc. (OTCQB: RLMD), a biopharmaceutical firm with four novel pain treatment drugs currently under development in its pipeline,...